arrow
T

Toshihiko Oki

AbbVie Inc.
H指数:29
被引数:3,773

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recurrent Genomic Alterations in BCRi-Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow-Up

接受维奈克拉治疗的BCRi经治CLL患者中复发性基因组改变:扩展的2期随访研究

2026-04-080
OAAI
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial

Epcoritamab单药治疗Richter转化(EPCORE CLL-1):一项单臂、多中心、开放标签的Ⅰb/Ⅱ期试验结果

2025-12-080
PRE
Discrimination of Dormant and Active Hematopoietic Stem Cells by G0 Marker Reveals Dormancy Regulation by Cytoplasmic Calcium
2019-12-0125
OAAI
A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors

一种新的生物可利用的芬维a胺制剂,对实体瘤具有抗增殖,抗代谢和细胞毒性作用

2019-07-2344
OAAI
Leukocyte mono-immunoglobulin-like receptor 8 (LMIR8)/CLM-6 is an FcRγ-coupled receptor selectively expressed in mouse tissue plasmacytoid dendritic cells
2018-05-297
OAAI
The CD300e molecule in mice is an immune-activating receptor
2018-03-0117
OAAI
Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment
2017-06-2724
OAAI
The molecular basis of myeloid malignancies

髓系恶性肿瘤的分子基础

2014-01-0119
OAAI
Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations
2013-10-08145
OA
Human CD300C Delivers an Fc Receptor-γ-dependent Activating Signal in Mast Cells and Monocytes and Differs from CD300A in Ligand Recognition
2013-03-0132
OAAI